Adlai Nortye (NASDAQ:ANL - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 216.90% from the stock's current price.
Adlai Nortye Trading Down 19.8 %
Shares of NASDAQ:ANL traded down $0.70 during midday trading on Monday, hitting $2.84. 79,525 shares of the stock were exchanged, compared to its average volume of 15,883. Adlai Nortye has a twelve month low of $1.85 and a twelve month high of $17.48. The company has a 50 day moving average price of $2.15 and a 200-day moving average price of $4.68.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
